Dr. Tony Coles is a founding investor and the chairman and CEO of Yumanity Therapeutics, a Cambridge, MA-based biotechnology company focused on transforming drug discovery for neurodegenerative diseases caused by protein misfolding such as Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis (ALS). Dr. Coles also serves as chairman and chief executive officer of TRATE Enterprises, a privately held company, and as chairman of the board of CRISPR Therapeutics.
Previously, Dr. Coles was chairman and CEO of Onyx Pharmaceuticals, which was acquired by Amgen in 2013. Prior to joining Onyx in 2008, he was president, CEO, and a member of the board of directors of NPS Pharmaceuticals. Before joining NPS in 2005, he served in various leadership positions at Vertex Pharmaceuticals, Bristol-Myers Squibb, and Merck & Co.
Educated at Johns Hopkins University, he earned an M.D. from Duke University and a master’s degree in public health from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.
Dr. Coles currently serves as a member of the board of directors of McKesson Corporation and Regeneron, and as a member of the board of trustees for Johns Hopkins Medicine. In 2015, Dr. Coles was named to the National Institutes of Health (NIH) working group tasked with charting the course for President Obama’s Precision Medicine Initiative, now part of the PMI Cohort Program Advisory Panel. Dr. Coles also serves as a member of the council for the Smithsonian’s National Museum of African American History and Culture, a member of the board of trustees for The Metropolitan Museum of Art, and a member of the board of directors of the Council on Foreign Relations.